In particular, since the T790M mutation seems to be critical for acquired resistance to EGFR-TKIs [11]–[15], the selection of antigen loss variants as immune escape might be avoided during immunotherapy and tumor evolution. This evidence concerns the gene EGFR and neoplasm.